Search

Displaying results 2261 - 2270 of 10000 in total
  1. Drug

    Tasonermin

    go.drugbank.com/drugs/DB11626
    Approved

    of the limbs as the product Beromun. … It was approved for use by the European Medicines Agency in April of 1999 for use as an adjunt to surgery for the subsequent removal of the tumor and in palliative care for irresectable soft tissue sarcoma

  2. Drug

    Maprotiline

    go.drugbank.com/drugs/DB00934
    Approved

    Maprotiline is effective at reducing symptoms of anxiety associated with depression.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeProducts: MAPROTILIN-NEURAX 25 MG, MAPROTILIN-NEURAX 50 MG
  3. Drug

    ADH-1

    go.drugbank.com/drugs/DB05485
    Investigational

    Poorly differentiated, highly invasive carcinomas are characterized by over-expression of N-cadherin (as opposed to E-cadherin). … ADH-1 may have utility in a wide variety of cancers as N-cadherin is overexpressed in a variety of tumors.

  4. Drug

    Ticlopidine

    go.drugbank.com/drugs/DB00208
    Approved

    Ticlopidine is an effective inhibitor of platelet aggregation. … Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who cannot take aspirin or in whom aspirin has not worked to prevent a thrombotic stroke.

    Categories: Metabolic Side Effects of Drugs and SubstancesProducts: TICLOPIDINA EG, TACRON TABLET 250 mg
  5. Drug

    Gemfibrozil

    go.drugbank.com/drugs/DB01241
    ApprovedInvestigational

    [L8525] Gemfibrozil was granted FDA approval on 21 December 1981.[L8525]

    Categories: Metabolic Side Effects of Drugs and SubstancesProducts: Nu-gemfibrozil Cap 300mg, Nu-gemfibrozil Tab 600mg
  6. Drug

    Trastuzumab emtansine

    go.drugbank.com/drugs/DB05773
    ApprovedInvestigational

    disease or had their cancer recur within 6 months of adjuvant treatment. … Second that there is a black box warning of serious side effects such as hepatotoxicity, embryo-fetal toxicity, and cardiac toxicity.

    Products: KADCYLA 100 MG IV INFUZYONLUK COZELTI KONSANTRESI ICIN TOZ, KADCYLA 160 MG IV INFUZYONLUK COZELTI KONSANTRESI ICIN TOZ
  7. Drug

    Prochlorperazine

    go.drugbank.com/drugs/DB00433
    ApprovedInvestigationalVet approved

    of psychotic disorders such as generalized non-psychotic anxiety and schizophrenia. … Prochlorperazine, also known as compazine, is a piperazine phenothiazine and first-generation antipsychotic drug that is used for the treatment of severe nausea and vomiting, as well as short-term management

    Products: Nu-prochlor Tab 5mg, Nu-prochlor Tab 10mg
  8. Drug

    Fidanacogene elaparvovec

    go.drugbank.com/drugs/DB16783
    ApprovedInvestigational

    soft tissues or joints, and severe subcutaneous hematomas. … from week 12 to month 15 compared to an ABR of 4.43 for the pre-treatment period.

  9. Drug

    Tiopronin

    go.drugbank.com/drugs/DB06823
    Approved

    It is used after a failure of the non-pharmacological first line treatment consisting of increased fluid intake, restriction of sodium and protein, and urinary alkalinization. … Tiopronin is dosed on an individual basis using close monitoring of urinary cystine concentrations and urinary output.

  10. Drug

    Clesrovimab

    go.drugbank.com/drugs/DB18877
    Approved

    [A273953,A273978] Clesrovimab-cfor was approved by the US FDA in June 2025 for use in infants prior to or during their first RSV season.[L53228,L53233] … Clesrovimab is a fully human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody targeted against the extracellular domain of the respiratory syncytial virus (RSV) fusion (F) protein.